posted
could have gone in for a flip but I agree schwab, safer to wait for the pull back. Pretty darn good contract though. Would have had .054 to .062, not too bad.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?
IP: Logged |
Today’s Price Performance as of 10:33am EDT, 9/12/2006 Option Chains Margin Requirements Interactive Chart
Loading Chart1 Day | 5 Day | 6 Mo | 1 Yr | 3 Yr | 5 Yr $0.055 Last Price 0.0021 +3.96% Today’s Change $0.05 Today’s Open 15,234,058 Above Avg. Today’s Volume
-------------------- All I say is IMHO.
I like these calm little moments before the storm... Reminds me of Bethoven
IP: Logged |
posted
I didn't get in, was thinking of getting in at .054 and would have gotten out at .062. Passed this one up since I missed the first big run. When this settles there should be another PR with how much rev is expected - thinking they will milk it for every penny. may jump in when it gets lower.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?
IP: Logged |
Grant Life Sciences enters into Memorandum of Understanding (MOU) with Chinese medical device company to manufacture and distribute Grant's point-of-care, rapid diagnostic tests in China and Hong Kong Wednesday September 13, 9:00 am ET "When finalized, this relationship will fit with Grant's new corporate strategy: to (1) acquire products and technologies via in-licensing activities and optimize these products and technologies (2) out-license them for further development and sales and (3) drive sales through our own established marketing channels." -Dr. Hun-Chi Lin, President and Chief Scientist, Grant Life Sciences
LOS ANGELES--(BUSINESS WIRE)--Sept. 13, 2006--Grant Life Sciences Inc. (OTC BB: GLIF - News) announced today that it has signed a Memorandum of Understanding (MOU) with GuongDong Kangermei Industry Development Co. Ltd. (GDK) to license the manufacturing and distribution rights of Grant's AccuDx line of rapid, point-of-care (POC) tests in China and Hong Kong. Below is a summary of the key terms of the MOU, which will be used as the basis for a definitive License and Collaboration Agreement between Grant and GDK:
* Grant agrees to license the manufacturing, distribution, and sales rights of certain AccuDx products for the territories of China and Hong Kong to GDK. The AccuDx products include POC tests to detect Hepatitis B and C, HIV 1 and 2, Dengue Fever, and heart attack markers Troponin 1 and Myoglobin. * Grant agrees to use GDK as an OEM (original equipment manufacturer) to produce AccuDx products for the markets outside of China and Hong Kong for an initial period of four years. * All products manufactured by GDK that are to be sold outside of China/Hong Kong shall be handled by Grant. * Grant will own an undisclosed percentage of equity in GDK. * GDK agrees that Grant will have one Director seat. * GDK agrees to pay Grant RMB$1.0 million upfront to facilitate technology transfer.
"When this MOU is finalized, we look forward to a long and mutually beneficial relationship between Grant and GDK," said Huok Xin, CEO of GDK.
"When completed, this relationship with GDK will fit with Grant Life Science's new corporate strategy: to (1) acquire new products and technologies through in-licensing activities and optimize these products and technologies; (2) out-license them for further development and sales; and (3) drive sales through our own established marketing channels," said Dr. Hun-Chi Lin, President and Chief Scientist, Grant Life Sciences. "We expect this relationship with GDK will enable Grant to gain access in China to a large consumer market for our technologies and products."
About GDK
GuongDong Kangermei Industry Development Co., Ltd. (GDK) is a medical device company located in GuongDong Province, China, and has established a manufacturing facility and distribution channel in China. GDK is principally involved in the manufacturing of medical instrument sets comprising single-use injection syringes and single-use blood and plasma transfusion sets.
About Grant Life Sciences
Grant Life Sciences Inc., a development stage company, engages in the research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company's products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.
Contact:
Grant Life Sciences Inc. Don Rutherford, 949-521-1232 CFO
Source: Grant Life Sciences Inc.
-------------------- One risk I enjoy: daytrading stocks
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
